Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era.

Front Oncol · 2025 · PMC12099209 · PMID 40416868

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

a nonsignificant trendp=0.053so close (0.05 < p ≤ 0.1)

12.6 months, p=0.015), while anti-PD1+chemotherapy (n=590) showed a nonsignificant trend towards improvement (median survival 14.3 vs. 12.6 months, p=0.053).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.